Clinical-stage personalized medicine and diagnostics company developing a blood-test platform to diagnose and monitor brain, neuropsychiatric, neurodegenerative, autoimmune, and vascular diseases
Clinical-stage personalized medicine and diagnostics company developing a blood-test platform to diagnose and monitor brain, neuropsychiatric, neurodegenerative, autoimmune, and vascular diseases. Its patented GLX Signature Platform measures glycocalyx fragments shed from blood vessel linings and uses AI/ML to generate disease-specific biomarker signatures and actionable clinical reports for diagnosis, monitoring, and treatment decisions.
The top three firms on F4's Biotech & Life Sciences investor list.